Storia della carriera di Douglas J. Ringler
Precedenti posizioni note di Douglas J. Ringler
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Fondatore | 23/03/2010 | 19/12/2011 |
| Presidente | 01/07/2000 | 19/12/2011 | |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 01/01/1998 |
| Fondatore | 01/01/1998 | 01/01/1998 |
Formazione di Douglas J. Ringler
| University of Pennsylvania | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
Posizioni
| Founder | 2 |
| President | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Douglas J. Ringler
- Esperienza
